Clozapine is an atypical antipsychotic drug that is effective in the treatment of schizophrenic patients who do not respond to conventional antipsychotic drugs (Kane et al. 1988; Baldessarini and Frankenburg 1991; Meltzer and Ranjan 1996) . Clozapine differs from typical antipsychotic drugs (APDs) by lacking any substantial extrapyramidal side effect (EPS) liability, and has been reported to be superior to typical APDs in reducing negative symptoms. The mechanisms that subserve the atypical APD profile of clozapine remain unclear (see Deutch et al. 1991; Fatemi et al. 1996).
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The metabolism of clozapine is predominantly hepatic, with several metabolites being generated (Fischer et al. 1992; DeVane 1995) . The major clozapine metabolites are N-desmethylclozapine and clozapine N-oxide (Centorrino et al. 1994; Pirmohamed et al. 1995) . The N-oxide is reduced back to clozapine in the presence of NADPH (Jann et al. 1994) . The other major metabolite, desmethylclozapine, is present in plasma concentrations that may exceed 40% of that of the parent compound in humans (Centorrino et al. 1994 ). Desmethylclozapine is the major metabolite in the rodent, and serum levels of desmethylclozapine average about 70% of the parent compound, with brain levels being comparable to serum levels (Baldessarini et al. 1993) . Despite the high plasma concentrations of desmethylclozapine in schizophrenic patients receiving clozapine treatment, and the positive correlation between plasma desmethylclozapine concentration and therapeutic outcome (Piscitelli et al. 1994) , it remains unclear if this clozapine metabolite has biological activity in vivo (DeVane 1995). Several studies have documented the activity of desmethylclozapine in various in vitro paradigms (Kuoppamaki et al. 1993; Gershon et al. 1994; Squires and Saederup 1991) , but conclusive evidence of in vivo activity is lacking. This question may have important ramifications for the mechanism of action of clozapine.
Clozapine differs from other APDs by increasing the expression of the immediate-early gene c-fos , or its protein product Fos, in the prefrontal cortex (PFC) (Robertson and Fibiger 1992; Deutch and Duman 1996; see Deutch 1996) . Clozapine also increases Fos levels in the shell compartment of the nucleus accumbens (NAS), a site where all APDs are thought to increase Fos expression (Deutch et al. 1992; Robertson et al. 1994; Guo et al. 1995) , and in the thalamic paraventricular nucleus (PV) (Deutch et al. 1995) . In contrast, clozapine does not increase Fos expression in the dorsolateral striatum, where typical APDs markedly increase Fos expression (Robertson and Fibiger 1992; Deutch et al. 1992; Nguyen et al. 1992) . These regionally distinct effects of antipsychotic drugs on Fos expression are seen in both rodent and primate species (Ikemoto et al. 1995; Deutch et al. 1996) .
The unique profile of clozapine-induced changes in forebrain Fos expression offers a convenient means of assessing pharmacological effects that are related to the mechanisms of action of clozapine (see Robertson et al. 1994 and Deutch 1996) . We therefore used Fos expression as an index of in vivo activity of desmethylclozapine.
MATERIALS AND METHODS

Animal Treatment
Adult male Sprague-Dawley rats (Camm; Wayne, NJ) were maintained on a 12:12 light:dark cycle, with food and water available ad libitum. On the test day, rats received subcutaneous injections of desmethylclozapine (7.5 or 30.0 mg/kg), clozapine (7.5 or 30.0 mg/kg), or pH-matched vehicle, and were killed 2 hours later. The combined infralimbic/prelimbic parts of the PFC were dissected as described previously (Deutch and Duman 1996) , as were the NAS, dorsolateral striatum, and thalamic paraventricular nucleus. Samples were stored at Ϫ 75 Њ C until assayed.
Immunoblot Analyses
Levels of Fos protein were determined by immunoblots, using a well-characterized antibody that recognizes Fos and several Fos-related antigens (Fras) (Quinn et al. 1989) . Western blots were performed on total protein from tissue homogenates of the brain samples. Briefly, the tissues were homogenized in 2% SDS, and protein levels were determined by the method of Lowry et al. (1951) . Equal amounts of protein (for each brain site) were then run on a 10% acrylamide/0.27% methylenebisacrylamide gel overnight at 67 V and transferred to nitrocellulose. Following steps to block nonspecific binding, the blots were incubated overnight at 4 Њ C in the primary antibody (1:5000). The next day the blots were washed in blocking buffer, incubated for 2 hours in horseradish peroxidase-conjugated secondary antibody (1:500), and then washed extensively before being developed using chemiluminescence with exposure to Hyperfilm-ECL.
Protein levels were quantitated by measuring band optical densities using computer-assisted densitometry on a Macintosh computer with the public domain NIH Image program (developed at the US National Institutes of Health and available on the Internet at http:// rsb.info.nih.gov/nih-image) after calibration on an optical step chart (Kodak). In some cases, depending upon the electrophoretic resolution on the films of the polyacrylamide gels, an apparent doublet was seen at ഠ 55 kD; this probably represents posttranslational modification of Fos. For the densitometric evaluation of Fos, we measured both bands collectively, because the two species are similarly regulated. Relative optical densities of the Fos bands were assessed; the levels of Fos-related antigens (Fras) were not analyzed, because changes in Fras in response to acute APD treatments remain to be well characterized. The optical densities were compared by means of one-way ANOVAs followed by planned comparisons, with experiment wise ␣ set at 0.05.
RESULTS
Acute administration of desmethylclozapine increased Fos protein levels in the PFC and NAS (see Figures 1  and 2) ; there was also a significant increase in Fos protein levels in the thalamic paraventricular nucleus (data not shown). Neither clozapine nor its metabolite increased Fos expression in the dorsolateral striatum (Figure 1) . The effects of desmethylclozapine were dose dependent in the responsive regions. In the PFC, the magnitude of desmethylclozapine-elicited Fos induction appeared to be somewhat greater than that observed after identical doses of clozapine, but this difference was not statistically significant. In contrast, in the NAS, the low dose of clozapine, but not desmethylclozapine, significantly increased Fos expression (see Figure  2) , as did the high doses of both clozapine and its metabolite. In the PFC and NAS, a band corresponding to Fos is seen in vehicle-treated animals. This band does not appear in the dorsolateral striatum and presumably reflects induction of the protein in response to the stress of the vehicle injection (unpublished observations), which is consistent with the known regionally specific effects of stress on c-fos expression (Cullinan et al. 1995) .
DISCUSSION
These data provide the first demonstration of in vivo biological activity of desmethylclozapine. The effects of desmethylclozapine on Fos protein expression paral- leled those of clozapine: the three brain areas in which clozapine elicited a response also responded to the desmethyl metabolite, whereas the dorsolateral striatum did not respond to either clozapine or its metabolite.
The functional significance of desmethylclozapine in vivo remains unclear. The metabolite may exert therapeutic actions. However, it is plausible that desmethylclozapine is responsible for certain side effects rather than therapeutic actions of clozapine. Desmethylclozapine strongly suppresses hematopoiesis in vitro at concentrations that are lower than those of clozapine and clozapine-N-oxide (Gershon et al. 1994) . Because clozapine treatment results in agranulocytosis in about 1% of patients (Alvir et al. 1993) , the suppression of hematopoiesis has fueled speculation that desmethylclozapine is responsible for the clozapine-induced blood dyscrasia. However, subsequent studies examining clozapine and desmethylclozapine plasma levels in patients who developed agranulocytosis failed to support this hypothesis (Hasegawa et al. 1994) .
The distinct pattern of Fos induction in response to desmethylclozapine, which faithfully reproduces that seen in response to clozapine challenge, suggests that the metabolite may possess (independently or cooperatively) antipsychotic actions. Previous studies of antipsychotic drugs have revealed that clozapine but not other APDs increases Fos expression in the PFC (Deutch and Duman 1996) ; both typical and atypical APDs increase Fos protein expression in the nucleus accumbens shell (Deutch et al. 1992; Robertson and Fibiger 1992) . The ability of clozapine to increase Fos in the forebrain has considerable predictive validity for APD actions, and a high degree of convergent validity when compared with several other tests of APD action (see Deutch 1996) . It is therefore possible that the ability of desmethylclozapine to induce Fos in selected brain regions reflects antipsychotic efficacy of the clozapine metabolite. This idea fits well with the excellent correlation between plasma levels of desmethylclozapine and reduction in psychotic symptomatology (Piscitelli et al. 1994) . Unfortunately, the high correlation between clozapine and its desmethyl and N-oxide metabolites (Centorrino et al. 1994 ) precludes definitive assessment of the relative contribution of the metabolites to antipsychotic efficacy; to resolve this question would appear to require clinical trials of desmethylclozapine.
Studies of the receptor affinities of desmethylclozapine have so far been restricted to certain serotonergic and dopaminergic receptors. Desmethylclozapine appears to have substantially higher affinities for D 2 -like receptors (as reflected by [ 3 H]spiperone binding) than does clozapine, but shows a reduced affinity for the D 1 receptor (Kuoppamaki et al. 1993 ). We are not aware of specific assessments of the affinities of desmethylclozapine for Figure 2 . The effects of clozapine (CLZ) and desmethylclozapine (DM) relative to vehicle (V) in the PFC and NAS. The significant increases are relative to vehicle-treated animals; there was no statistically significant difference in the magnitude of the response to clozapine or its metabolite at a given dose. *p р .05. **p р .01. the different types of dopamine receptors in the D 1 or D 2 class. The observation that desmethylclozapine has a higher affinity for D 2 but lower affinity for D 1 receptors is congruent with current understanding of the actions of APDs: D 2 -like receptors clearly have a role in antipsychotic drug action, whereas a recent open trial has suggested that selective D 1 receptor antagonists lack therapeutic efficacy .
In addition, desmethylclozapine has higher affinities for the 5-HT 2a and 5-HT 2c receptors than the parent compound (Kuoppamaki et al. 1993) . These shifts in serotonin receptor affinity parallel those seen in D 2 affinity. Thus, desmethylclozapine and its parent compound have approximately the same high ratio of 5-HT 2a :D 2 affinities, a characteristic of APDs that display low EPS liability but continued antipsychotic efficacy (Meltzer et al. 1989) . It is interesting to note that the higher affinity of desmethylclozapine for the D 2 receptor does not appear to be sufficient to induce Fos in the dorsolateral striatum; this may be due to its increased affinity for the 5-HT2 2a receptor, thus maintaining a favorable 5-HT 2a :D 2 profile (Meltzer et al. 1989 ). Alternatively, it is possible that the lack of striatal Fos expression in response to desmethylclozapine is due to partial occupancy of striatal D 2 receptors, as has been reported for clozapine in imaging and postmortem studies (Farde et al. 1992; Hall et al. 1995; Nordstrom et al. 1995) .
In summary, the ability of desmethylclozapine to induce Fos protein in selected brain regions provides evidence of the in vivo activity of the clozapine metabolite. Although the functional effects of desmethylclozapine remain unknown, the in vivo activity of the metabolite, coupled with the high plasma concentrations and brain levels, suggests that further attention be devoted to elucidating the functional role(s) of desmethylclozapine.
Deutch AY (1996) 
